1. Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients
- Author
-
Fagyas, Miklós, Bánhegyi, Viktor, Úri, Katalin, Enyedi, Attila, Lizanecz, Erzsébet, Mányiné, Ivetta Siket, Mártha, Lilla, Fülöp, Gábor Áron, Radovits, Tamás, Pólos, Miklós, Merkely, Béla, Kovács, Árpád, Szilvássy, Zoltán, Ungvári, Zoltán, Édes, István, Csanádi, Zoltán, Boczán, Judit, Takács, István, Szabó, Gábor, Balla, József, Balla, György, Seferovic, Petar, Papp, Zoltán, and Tóth, Attila
- Subjects
Male ,SARS-CoV-2 ,COVID-19 ,Heart failure ,Stroke Volume ,Cardiovascular disease ,Ventricular Function, Left ,Renin-Angiotensin System ,Angiotensin converting enzyme 2 (ACE2) ,Hypertension ,Humans ,Original Article ,Female ,Angiotensin-Converting Enzyme 2 ,RAAS inhibitors ,Renin-angiotensin-aldosterone system (RAAS) ,hormones, hormone substitutes, and hormone antagonists ,Biomarkers ,Aged - Abstract
Angiotensin-converting enzyme 2 (ACE2) is essential for SARS-CoV-2 cellular entry. Here we studied the effects of common comorbidities in severe COVID-19 on ACE2 expression. ACE2 levels (by enzyme activity and ELISA measurements) were determined in human serum, heart and lung samples from patients with hypertension (n = 540), heart transplantation (289) and thoracic surgery (n = 49). Healthy individuals (n = 46) represented the controls. Serum ACE2 activity was increased in hypertensive subjects (132%) and substantially elevated in end-stage heart failure patients (689%) and showed a strong negative correlation with the left ventricular ejection fraction. Serum ACE2 activity was higher in male (147%), overweight (122%), obese (126%) and elderly (115%) hypertensive patients. Primary lung cancer resulted in higher circulating ACE2 activity, without affecting ACE2 levels in the surrounding lung tissue. Male sex resulted in elevated serum ACE2 activities in patients with heart transplantation or thoracic surgery (146% and 150%, respectively). Left ventricular (tissular) ACE2 activity was unaffected by sex and was lower in overweight (67%), obese (62%) and older (73%) patients with end-stage heart failure. There was no correlation between serum and tissular (left ventricular or lung) ACE2 activities. Neither serum nor tissue (left ventricle or lung) ACE2 levels were affected by RAS inhibitory medications. Abandoning of ACEi treatment (non-compliance) resulted in elevated blood pressure without effects on circulating ACE2 activities. ACE2 levels associate with the severity of cardiovascular diseases, suggestive for a role of ACE2 in the pathomechanisms of cardiovascular diseases and providing a potential explanation for the higher mortality of COVID-19 among cardiovascular patients. Abandoning RAS inhibitory medication worsens the cardiovascular status without affecting circulating or tissue ACE2 levels.
- Published
- 2021